Published in Blood Weekly, December 12th, 2002
Gen-Probe developed this amplified assay based on its proprietary Transcription-Mediated Amplification (TMA) technology. The Qualitative HCV Assay, which will be marketed by Bayer Corporation, Diagnostics Division, under the brand name Versant, is to be used by clinical laboratories to detect the presence of HCV in human plasma or serum in patients suspected to be actively infected with HCV or with evidence of the HCV infection.
Positive results from a clinical study of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.